Ole K Jensen1,2, Morten H Andersen3, René D Østgård3, Niels T Andersen4, Nanna Rolving5. 1. Spine Center, Research Unit, University Research Clinic for Innovative Patient Pathways, Silkeborg Regional Hospital, Silkeborg, Denmark. 2. , Risskov, Denmark. 3. University Research Clinic for Innovative Patient Pathways, Silkeborg Regional Hospital, Silkeborg, Denmark. 4. Department of Biostatistics, University of Aarhus, Aarhus, Denmark. 5. DEFACTUM, Central Denmark Region, Aarhus, Denmark.
Abstract
PURPOSE: To investigate whether treatment by lactic acid bacteria for 100 days is associated with change of disability and pain in chronic low back pain (CLBP) patients with type 1 or mixed Modic changes (MC) during 1-year follow-up. METHODS:Eighty-nine patients with CLBP and type 1 MC or mixed MC were randomized to receive either one capsule Lactobacillus Rhamnosis GG (6 billion colony-forming unit per capsule) twice daily or placebo capsules for 100 days. RESULTS: Missing values at 1 year were 4% and 3% in the disability and pain variables, respectively. The predefined outcomes disability and back + leg pain only changed little during follow-up with no statistically significant differences between groups. At 1 year, back pain had on average decreased by 1.1 more on a 0-10 scale (95% confidence interval 0.20-1.97) in the group treated by lactic acid bacteria than in the control group. There were no differences regarding other predefined outcomes, i.e. global effect or percentage with minimal disability at 1 year. Nine per cent of the patients reported gastrointestinal side effects without difference between groups. CONCLUSIONS: No differences were found regarding the predefined outcomes. Overall, there was little improvement during the 1-year observation period. A small, though hardly clinically relevant, effect on back pain was seen after treatment by Lactobacillus Rhamnosis GG, and the treatment was without side effects in comparison with the control group.
RCT Entities:
PURPOSE: To investigate whether treatment by lactic acid bacteria for 100 days is associated with change of disability and pain in chronic low back pain (CLBP) patients with type 1 or mixed Modic changes (MC) during 1-year follow-up. METHODS: Eighty-nine patients with CLBP and type 1 MC or mixed MC were randomized to receive either one capsule Lactobacillus Rhamnosis GG (6 billion colony-forming unit per capsule) twice daily or placebo capsules for 100 days. RESULTS: Missing values at 1 year were 4% and 3% in the disability and pain variables, respectively. The predefined outcomes disability and back + leg pain only changed little during follow-up with no statistically significant differences between groups. At 1 year, back pain had on average decreased by 1.1 more on a 0-10 scale (95% confidence interval 0.20-1.97) in the group treated by lactic acid bacteria than in the control group. There were no differences regarding other predefined outcomes, i.e. global effect or percentage with minimal disability at 1 year. Nine per cent of the patients reported gastrointestinal side effects without difference between groups. CONCLUSIONS: No differences were found regarding the predefined outcomes. Overall, there was little improvement during the 1-year observation period. A small, though hardly clinically relevant, effect on back pain was seen after treatment by Lactobacillus Rhamnosis GG, and the treatment was without side effects in comparison with the control group.
Authors: Stefan Dudli; Ellen Liebenberg; Sergey Magnitsky; Steve Miller; Sibel Demir-Deviren; Jeffrey C Lotz Journal: J Orthop Res Date: 2016-08-03 Impact factor: 3.494
Authors: Juhani H Määttä; Sam Wadge; Alex MacGregor; Jaro Karppinen; Frances M K Williams Journal: Spine (Phila Pa 1976) Date: 2015-08-01 Impact factor: 3.468
Authors: Rikke K Jensen; Charlotte Leboeuf-Yde; Niels Wedderkopp; Joan S Sorensen; Tue S Jensen; Claus Manniche Journal: Eur Spine J Date: 2012-04-24 Impact factor: 3.134
Authors: Damian Hoy; Lyn March; Peter Brooks; Fiona Blyth; Anthony Woolf; Christopher Bain; Gail Williams; Emma Smith; Theo Vos; Jan Barendregt; Chris Murray; Roy Burstein; Rachelle Buchbinder Journal: Ann Rheum Dis Date: 2014-03-24 Impact factor: 19.103
Authors: Roger Chou; Richard Deyo; Janna Friedly; Andrea Skelly; Robin Hashimoto; Melissa Weimer; Rochelle Fu; Tracy Dana; Paul Kraegel; Jessica Griffin; Sara Grusing; Erika D Brodt Journal: Ann Intern Med Date: 2017-02-14 Impact factor: 25.391
Authors: Per Martin Kristoffersen; Lars C H Bråten; Nils Vetti; Lars Grøvle; Christian Hellum; Kjersti Storheim; John-Anker Zwart; Jörg Assmus; Ansgar Espeland Journal: Eur Radiol Date: 2020-11-27 Impact factor: 5.315